CN115052866A - 含氮杂芳类衍生物自由碱的晶型 - Google Patents
含氮杂芳类衍生物自由碱的晶型 Download PDFInfo
- Publication number
- CN115052866A CN115052866A CN202180011135.6A CN202180011135A CN115052866A CN 115052866 A CN115052866 A CN 115052866A CN 202180011135 A CN202180011135 A CN 202180011135A CN 115052866 A CN115052866 A CN 115052866A
- Authority
- CN
- China
- Prior art keywords
- degrees
- amino
- cycloalkyl
- radical
- diffraction peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Liquid Crystal Substances (AREA)
Abstract
本发明涉及一种含氮杂芳类衍生物自由碱的晶型。具体涉及一种具有通式(I)化合物自由碱的晶型、制备方法和含有治疗有效量的该晶型的药物组合物,及其作为蛋白酪氨酸磷酸酶‑2C(SHP2)抑制剂,在治疗白血病、神经母细胞瘤、黑色素瘤、乳癌、肺癌及其结肠癌等疾病或病症的用途。
Description
PCT国内申请,说明书已公开。
Claims (23)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010261479X | 2020-04-03 | ||
CN202010261479 | 2020-04-03 | ||
PCT/CN2021/085155 WO2021197452A1 (zh) | 2020-04-03 | 2021-04-02 | 含氮杂芳类衍生物自由碱的晶型 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115052866A true CN115052866A (zh) | 2022-09-13 |
Family
ID=77929838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180011135.6A Pending CN115052866A (zh) | 2020-04-03 | 2021-04-02 | 含氮杂芳类衍生物自由碱的晶型 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230134869A1 (zh) |
EP (1) | EP4129987A4 (zh) |
JP (1) | JP2023521023A (zh) |
KR (1) | KR20220163985A (zh) |
CN (1) | CN115052866A (zh) |
AU (1) | AU2021245897A1 (zh) |
CA (1) | CA3173060A1 (zh) |
TW (1) | TW202144334A (zh) |
WO (1) | WO2021197452A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230011245A (ko) | 2021-07-09 | 2023-01-20 | 주식회사 카나프테라퓨틱스 | Shp2 억제제 및 이의 용도 |
CN118019537A (zh) * | 2021-09-28 | 2024-05-10 | 上海翰森生物医药科技有限公司 | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 |
CN117088887A (zh) * | 2022-05-20 | 2023-11-21 | 安徽中科拓苒药物科学研究有限公司 | Shp2抑制剂及其用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107495A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN109983001A (zh) * | 2016-07-12 | 2019-07-05 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
CN110143949A (zh) * | 2018-05-09 | 2019-08-20 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2020073949A1 (zh) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112625028A (zh) * | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
WO2019051084A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
-
2021
- 2021-04-01 TW TW110112260A patent/TW202144334A/zh unknown
- 2021-04-02 JP JP2022560096A patent/JP2023521023A/ja active Pending
- 2021-04-02 CA CA3173060A patent/CA3173060A1/en active Pending
- 2021-04-02 US US17/914,671 patent/US20230134869A1/en active Pending
- 2021-04-02 EP EP21781797.2A patent/EP4129987A4/en active Pending
- 2021-04-02 KR KR1020227037321A patent/KR20220163985A/ko unknown
- 2021-04-02 CN CN202180011135.6A patent/CN115052866A/zh active Pending
- 2021-04-02 AU AU2021245897A patent/AU2021245897A1/en active Pending
- 2021-04-02 WO PCT/CN2021/085155 patent/WO2021197452A1/zh active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107495A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
CN105916845A (zh) * | 2014-01-17 | 2016-08-31 | 诺华股份有限公司 | 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物 |
CN109983001A (zh) * | 2016-07-12 | 2019-07-05 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
CN110143949A (zh) * | 2018-05-09 | 2019-08-20 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2020073949A1 (zh) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2023521023A (ja) | 2023-05-23 |
US20230134869A1 (en) | 2023-05-04 |
AU2021245897A1 (en) | 2022-10-06 |
KR20220163985A (ko) | 2022-12-12 |
TW202144334A (zh) | 2021-12-01 |
CA3173060A1 (en) | 2021-10-07 |
EP4129987A1 (en) | 2023-02-08 |
EP4129987A4 (en) | 2024-05-15 |
WO2021197452A1 (zh) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111295374B (zh) | 含氮杂芳类衍生物调节剂、其制备方法和应用 | |
CN111295384B (zh) | 双环类衍生物抑制剂、其制备方法和应用 | |
TWI765908B (zh) | 苯並咪唑類化合物激酶抑制劑及其製備方法和應用 | |
CN112368283B (zh) | 含二并环类衍生物抑制剂、其制备方法和应用 | |
WO2021219091A2 (zh) | 喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂 | |
WO2021197452A1 (zh) | 含氮杂芳类衍生物自由碱的晶型 | |
CN113493440A (zh) | 含氮杂芳类衍生物的盐及其晶型 | |
CN114867720A (zh) | 杂芳基类衍生物及其制备方法和用途 | |
TW202214608A (zh) | 稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用 | |
CN116888108B (zh) | 新型egfr降解剂 | |
WO2013016999A1 (zh) | 杂芳基并嘧啶类衍生物、其制备方法和用途 | |
CN113748110A (zh) | 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 | |
KR20240051987A (ko) | 질소-함유 헤테로사이클릭 유도체 억제제, 이의 제조 방법 및 이의 용도 | |
WO2022111526A1 (zh) | 一种苯环衍生物及其组合物和药学上的应用 | |
JP2020525469A (ja) | 新規キノリノン化合物 | |
TW202308655A (zh) | 膦醯衍生物及其組合物和藥學上的應用 | |
CN113072551A (zh) | 含氮联苯类衍生物抑制剂、其制备方法和应用 | |
WO2022100738A1 (zh) | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 | |
CN112574208B (zh) | 取代的稠合三环衍生物及其组合物及用途 | |
KR20230039675A (ko) | Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물 | |
WO2022127807A1 (zh) | 一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用 | |
CN117229295A (zh) | 含氮大环类化合物及其制备方法和医药用途 | |
TW202400579A (zh) | 含氮雜環類衍生物抑制劑、其製備方法和應用 | |
CN114716370A (zh) | 含吡啶多环类衍生物抑制剂、其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40071313 Country of ref document: HK |